Phase 2 Trial of Selinexor Shows Durable Responses in DLBCL

August 21, 2020

Michael Schuster, MD, discusses the efficacy of treatment with selinexor in patients with diffuse large B-cell lymphoma in the SADAL study.

Michael Schuster, MD, director of the Bone Marrow Transplant Program at Stony Brook Cancer Center, discusses the efficacy of treatment with selinexor (Xpovio) in patients with diffuse large B-cell lymphoma (DLBCL) in the SADAL study (NCT02227251).

Schuster says that the good news is, for this heavily pre-treated population, almost a quarter of those patients had a response to selinexor. Some patients also went into complete remission (CR). These CRs went over 2 years without any evidence of progression of the disease. There were 2 patients in their 70s with heavily pretreated disease who both went into CR and are now approaching 2 years without any evidence of progression.

The most interesting thing is that this drug has a novel mechanism of action, according to Schuster. That is something that physicians can give to patients with DLBCL who have already been through chemotherapy regimens. He hopes that they can respond to this drug with a novel mechanism of action, and if they do respond that the response has a significant duration. Also, because selinexor is an oral agent, it is something that patients can take at home rather than having to come into the hospital for intravenous chemotherapy.

<< View more resources and information regarding DLBCL